Matinas BioPharma Holdings Inc (MTNB) FinancialsMTNBMatinas BioPharma Holdings Inc

Evaluating the bottom line, Matinas BioPharma Holdings Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -154.28%, provide a clear picture of how effectively MTNB converts its operational activities into shareholder value.

In the context of the broader market, MTNB competes directly with industry leaders such as SPRC and OGEN. With a market capitalization of $1.22M, it holds a significant position in the sector. When comparing efficiency, MTNB's gross margin of N/A stands against SPRC's N/A and OGEN's N/A. Such benchmarking helps identify whether Matinas BioPharma Holdings Inc is trading at a premium or discount relative to its financial performance.

Matinas BioPharma has shown continuous losses, with net income to common reaching -$8.43 million in Q4 2024 and -$1.32 million in Q2 2026. The gross profit has been negative in multiple quarters, indicating ongoing financial struggles.